Leukemia clinical trials

452 recruiting studies in the US for leukemia, cancers of the blood-forming tissues.

Leukemia research is dominated by early-phase treatment trials — Phase 1 and combined Phase 1/2 studies of targeted drugs and cellular therapies like CAR-T. Eligibility depends closely on leukemia type (such as AML, ALL or CLL), genetic markers and prior treatment lines. Many studies run at major cancer centers, so travel may be part of the plan.

Top locations

By phase

Showing 40 of 452 studies

RecruitingPhase 2NCT06124157

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Phoenix, AZ · Tucson, AZ · +141 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Tucson, AZ · +222 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Anchorage, AK · Mesa, AZ · +113 more sites

RecruitingPhase 1NCT06834282

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Sponsor: CERo Therapeutics Holdings, Inc.

Sacramento, CA · Denver, CO · Nashville, TN · +2 more sites

RecruitingPhase 1NCT07572136

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 3NCT04269902

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Anchorage, AK · +621 more sites

RecruitingPhase 3NCT06395441

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

Sponsor: Mayo Clinic

Albert Lea, MN · Bemidji, MN · Brainerd, MN · +12 more sites

RecruitingNot applicableNCT06421155

Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

Sponsor: Case Comprehensive Cancer Center

Cleveland, OH

RecruitingPhase 1NCT06543381

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Sponsor: City of Hope Medical Center

Duarte, CA · Cleveland, OH

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Birmingham, AL · Anchorage, AK · +452 more sites

RecruitingPhase 1NCT06575296

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 1NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1NCT07012044

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Aurora, CO · Atlanta, GA · +11 more sites

RecruitingPhase 2NCT07328503

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase not listedNCT00923507

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Bethesda, MD

RecruitingPhase not listedNCT01087333

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase not listedNCT02682667

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1 / Phase 2NCT05442515

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Tucson, AZ · +172 more sites

RecruitingPhase not listedNCT05588154

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1 / Phase 2NCT06364423

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.

Duarte, CA · Tampa, FL · Buffalo, NY · +6 more sites

RecruitingPhase 1NCT07133997

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 1NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Sponsor: National Cancer Institute (NCI)

Atlanta, GA · City of Saint Peters, MO · +16 more sites

RecruitingPhase 2NCT04728893

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Sponsor: Merck Sharp & Dohme LLC

Springdale, AR · La Jolla, CA · Torrance, CA · +8 more sites

RecruitingPhase 3NCT05947851

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Sponsor: Merck Sharp & Dohme LLC

Springdale, AR · Long Beach, CA · Clermont, FL · +22 more sites

RecruitingPhase 1NCT06528301

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor: Umoja Biopharma

Duarte, CA · Chicago, IL · Grand Rapids, MI · +4 more sites

RecruitingPhase 2NCT06691217

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Sponsor: Massachusetts General Hospital

Boston, MA

RecruitingPhase 1 / Phase 2NCT07109219

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Sponsor: AstraZeneca

Duarte, CA · Jacksonville, FL · Chicago, IL · +3 more sites

RecruitingPhase 2NCT07354074

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Sponsor: Novartis Pharmaceuticals

New Brunswick, NJ · New York, NY · Cincinnati, OH · +1 more sites

RecruitingPhase 1NCT07424833

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Sponsor: Ascentage Pharma Group Inc.

Los Angeles, CA · Jacksonville, FL · Grand Rapids, MI · +2 more sites

RecruitingPhase 1NCT07532525

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Sponsor: University of Michigan Rogel Cancer Center

Ann Arbor, MI

RecruitingPhase 1NCT07723703

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Sponsor: Amphista Therapeutics Ltd

Fairfax, VA

RecruitingPhase 1NCT05188170

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Sponsor: Stanford University

Palo Alto, CA

RecruitingPhase 2NCT06128070

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase not listedNCT00131014

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Sponsor: Dana-Farber Cancer Institute

Boston, MA

RecruitingPhase 1NCT02390635

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase not listedNCT04028531

Understanding Chronic Lymphocytic Leukemia

Sponsor: Dana-Farber Cancer Institute

Boston, MA

RecruitingPhase not listedNCT05724121

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Bethesda, MD

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Mobile, AL · Gilbert, AZ · Phoenix, AZ · +46 more sites

Related conditions

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.